Thromb Haemost 1981; 46(04): 749-751
DOI: 10.1055/s-0038-1653468
Original Article
Schattauer GmbH Stuttgart

GAGs-Potentiated Inhibition of Thrombin, Factor Xa and Plasmin in Plasma and in a Purified System Containing Antithrombin III – Correlation with Total Charge Density

E Cofrancesco
The Istituto Clinica Medica I, Università di Milano, Italy
,
A Vigo
The Istituto Clinica Medica I, Università di Milano, Italy
,
E M Pogliani
The Istituto Clinica Medica I, Università di Milano, Italy
› Author Affiliations
Further Information

Publication History

Received 17 August 1981

Accepted 28 October 1981

Publication Date:
05 July 2018 (online)

Summary

The ability of heparin and related glycosaminoglycans (GAGs) to accelerate the inhibition of thrombin, factor Xa and plasmin in plasma and in a purified system containing antithrombin III (At III) was studied using chromogenic peptide substrate assays

There was a good correlation between the charge density of the mucopolysaccharides and the activities investigated. While the difference between potentiation of the antithrombin activity by GAGs in plasma and in the purified system was slight, the inhibition of factor Xa in plasma was more pronounced than in the presence of purified At III, indicating the mechanisms for GAGs-potentiated inhibition of thrombin and factor Xa are not identical.

For the antiplasmin activity, there was a good correlation between the chemical structure and biological activity only in the pure system, confirming that the antithrombin-GAG complex plays a very limited role in the inactivation of plasmin in plasma.

 
  • References

  • 1 Rosenberg RD. Biologic actions of heparin. Semin Hematol 1977; 14: 427-440
  • 2 Long WF, Williamson FB, Kindness G, Edward M. The anticoagulant activity of dermatan sulphates. Thromb Res 1980; 18: 493-503
  • 3 Teien AN, Abildgaard U, Hook M. The anticoagulant effect of heparan sulfate and dermatan sulfate. Thromb Res 1976; 8: 859-867
  • 4 Cofrancesco E, Radaelli F, Pogliani E, Amid N, Torri G G, Casu B. Correlation of sulfate content and degree of carboxylation of heparin and related glycosaminoglycans with anticomplement activity. Relationships to the anticoagulant and platelet aggregating activities Thromb Res 1979; 14: 179-187
  • 5 Ødegard OR. Evaluation of an amidolytic heparin cofactor assay method. Thromb Res 1975; 7: 351-360
  • 6 Ødegard OR, Abildgaard U. Determination of antithrombin III and antifactor Xa activity. In: New methods for the analysis of coagulation using chromogenic substrates. pp 123-141 de Gruyter; 1977
  • 7 Ødegard OR, Lie M, Abildgaard U. Heparin cofactor activity measured with an amidolytic method. Thromb Res 1975; 6: 287-294
  • 8 Ødegard OR, Lie M, Abildgaard U. Antifactor Xa activity measured with amidolytic methods. Haemostasis 1976; 5: 265-275
  • 9 Teger-Nilsson AC, Friberger P, Gyzander E. Determination of a new rapid plasma inhibitor in human blood by means of a plasmin specific tripeptide substrate. Scand J Clin Lab Invest 1977; 37: 403-409
  • 10 Andersson LO, Barrowcliffe TW, Holmer E, Johnson EA, Soderstrom G. Molecular weight dependency of the heparin potentiated inhibition of thrombin and activated factor X. Effect of heparin neutralization in plasma Thromb Res 1979; 15: 531-541
  • 11 Cifonelli JA. The relationship of molecular weight and sulfate content and distribution to anticoagulant activity of heparin preparations. Carbohydr Res 1974; 37: 145-151
  • 12 villanueva GB, Danishetsky I. Differencial effect of high affinity heparin and low affinity heparin on methylene blue titration. Thromb Res 1981; 21: 191-199
  • 13 Abildgaard U. Heparin, antithrombins and other physiological inhibitors. In: Haemostasis and Thrombosis. Neri Serner GG, Prentice CR M. (Eds) pp 169-176 Academic Press; 1979
  • 14 Semeraro N, Colucci M, Telesforo P, Collen D. The inhibition of plasmin by antithrombin-heparin complex. Br J Haematol 1978; 39: 91-99
  • 15 Naito K, Aoki N. Assay of α2-plasmin inhibitor activity by means of a plasmin specific tripeptide substrate. Thromb Res 1978; 12: 1147-1156
  • 16 Teger-Nilsson AC, Gyzander E, Hedner U, Myrwold H, Noppa H, Olsson R, Wallmo L. Antiplasmin and other naturally inhibitor of fibrinolysis in clinical material. In: Progress in chemical fibrinolysis and thrombolysis 1978; 3: 327-335
  • 17 Hook M, Bjork I, Hopwood J, Lindahl U. Anticoagulant activity of heparin. Separation of high-activity and low-activity species by affinity chromatography on immobilized antithrombin FEBS Lett 1976; 66: 90-93